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ABSTRACT
The presence of PER-1- and OXA-10-like b-lactamases was investigated by PCR in 49 ceftazidime-
resistant Pseudomonas aeruginosa isolates from patients hospitalised in the 24-bed general intensive care
unit of the Istanbul Faculty of Medicine during a 12-month period between February 1999 and February
2000. The clonal relatedness of the isolates was investigated by random ampliﬁed polymorphic DNA
(RAPD) analysis, and the sequences of the PER-1 and OXA genes from all isolates were determined. The
rates of resistance of the isolates to imipenem, aztreonam and cefepime were 98%, 92% and 96%,
respectively, and to piperacillin and piperacillin–tazobactam were 41% and 37%, respectively. Using the
double-disk synergy test, 37% (18 ⁄ 49) of the isolates were identiﬁed as extended-spectrum b-lactamase
producers. The PER-1 gene was identiﬁed in 86% (42 ⁄ 49) and the OXA-10 gene in 55% (27 ⁄ 49) of the
ceftazidime-resistant isolates. Of isolates carrying the PER-1 gene, 48% (20 ⁄ 42) also carried the OXA-10
gene. The respective nucleotide sequences were identical for each isolate. Sixteen RAPD patterns were
detected among the PER-1-positive isolates, but 60% (25 ⁄ 42) of the PER-1-positive isolates belonged to
two distinct patterns, while the remainder exhibited a wide clonal diversity. The results indicated that
the prevalence of PER-1- and OXA-10-like b-lactamases remains high among ceftazidime-resistant
P. aeruginosa isolates in Turkey.
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INTRODUCTION
Pseudomonas aeruginosa is involved frequently in
nosocomial infections, and there is an increasing
trend in this species towards multidrug resist-
ance. The most frequent mechanisms of acquired
resistance are overproduction of the derepressed
AmpC cephalosporinase, overexpression of the
MexA–MexB–OprM efﬂux system, a porin D2
deﬁciency and the production of transferable
b-lactamases [1,2]. b-Lactamases with broad-spec-
trum activity have been reported in P. aeruginosa.
These enzymes are clavulanic acid-inhibited
extended-spectrum b-lactamases (ESBLs) of
Ambler class A, metallo-enzymes of Ambler class
B, and expanded-spectrum oxacillinases of
Ambler class D [3].
Class A enzymes reported in P. aeruginosa
include PER-1, TEM-4, TEM-21, TEM-24, TEM-42,
SHV-2a, SHV-5, SHV-12, VEB-1, GES-1, GES-2 and
IBC-2 [4–7]. PER-1 b-lactamase was ﬁrst reported
from France in 1993 in a single P. aeruginosa isolate
from a Turkish patient [7], and was subsequently
isolated repeatedly in Turkey in the succeeding
years [9,10]. PER-1 has strong hydrolytic activity
against cephalosporins but, like most ESBLs of the
TEM and SHV type, cannot hydrolyse carbapen-
ems and cephamycins [11].
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The ESBLs OXA-11, OXA-14, OXA-16, OXA-17,
OXA-19 and OXA-28 are related structurally to
OXA-10, whereas OXA-15 and OXA-32 are rela-
ted to OXA-2 [12–18]. The activity of these serine
b-lactamases is inhibited weakly by clavulanic
acid, unlike that of OXA-18, which is inhibited
strongly by clavulanate [19]. These oxacillinase
genes are plasmid and ⁄ or integron-encoded.
b-Lactamases OXA-18, OXA-19, OXA-28 and
OXA-32 were identiﬁed in France, whereas the
others were identiﬁed in P. aeruginosa isolates
from Turkey [13–17]. The epidemiology of these
enzymes is unknown, and their isolation may
reﬂect the interest of the research team more than
a speciﬁc distribution of these expanded-spec-
trum enzymes.
The purpose of the present study was to
investigate the prevalence of PER-1- and OXA-
10-related b-lactamase genes in clinical isolates of
P. aeruginosa from patients hospitalised in the
intensive care unit (ICU) of the 1550-bed hospital
of the Istanbul Faculty of Medicine during a
12-month period, and to analyse their clonal
distribution.
MATERIALS AND METHODS
Bacterial strains and susceptibility testing
In total, 287 clinical isolates of P. aeruginosawere obtained from
patients hospitalised between February 1999 and February
2000. Forty-nine ICU isolates resistant to multiple drugs,
including ceftazidime, were included in the study. Isolates
were obtained from tracheal aspirates (n = 45), urinary tract
(n = 3) and bronchoalveloar lavage (n = 1) specimens. Coloni-
sation and infection were deﬁned as colony counts of
< 105 CFU ⁄mL and ‡ 105 CFU ⁄mL, respectively, following
quantitative culture of the clinical specimens [20]. The isolates
were identiﬁed with ID32 GN strips (bioMe´rieux, Marcy
l’Etoile, France), and susceptibility testing was performed
with the disk diffusion test recommended by the British
Society for Antimicrobial Chemotherapy [21]. ESBL produc-
tion was tested with the double-disk synergy test on Mueller–
Hinton agar [21] in which disks containing 30 lg of ceftaz-
idime or aztreonam were placed 25–30 mm apart from a disk
containing ticarcillin plus clavulanic acid (75 + 10 lg).
Enlargement of the inhibition zones of ceftazidime and ⁄ or
aztreonam towards the clavulanate-containing disk was inter-
preted as presumptive evidence for ESBL production.
PCRs and random ampliﬁed polymorphic DNA (RAPD)
analyses
Total DNA was extracted from the P. aeruginosa isolates as
described previously [8]. PCR ampliﬁcation of the PER-1 gene
was with primers PERA, 5¢-ATGAATGTCATTATAAAAGC-
3¢, and PERD, 5¢-AATTTGGGCTTAGGGCAGAA-3¢, yielding a
926-bp product. Primers used for ampliﬁcation of the OXA-10-
like genes (OXA-10, -11, -14, -16 and -17) were OPR1,
5¢-GTCTTTCGAGTACGGCATTA-3¢, and OPR2, 5¢-ATTTTC-
TTAGCGGCAACTTAC-3¢, yielding a 720-bp product. Ampli-
ﬁcation reactions were carried out with 1 U of Taq DNA
polymerase in a ﬁnal volume of 50 lL. PCR conditions were
10 min at 94C, followed by 35 cycles of 1 min at 94C, 1 min at
55C and 1 min at 72C, followed by a ﬁnal extension for
10 min at 72C.
The clonal relatedness of the PER-1-positive isolates was
investigated by RAPD analysis with the ERIC-2 primer
(5¢-AAGTAAGTGACTGGGGTGAGCG-3¢) and an ampliﬁca-
tion protocol of 5 min at 94C and 1 min at 36C, followed
by 35 cycles of 1 min at 94C, 90 s at 36C, and 3 min at
72C.
Agarose gel electrophoresis was carried out in conventional
Tris–acetate–EDTA (TAE) buffer with agarose 1% w ⁄v for
PER-1- and OXA-10-like PCR products, and agarose 1.5% w ⁄v
for the RAPD analyses. A 1-kb DNA ladder mix (Amersham
Pharmacia Biotech, Little Chalfont, UK) was used to provide
molecular size markers. The gels were stained with ethidium
bromide and observed under UV transillumination.
Sequencing of the blaPER-1 and blaOXA-10 genes
The DNA sequences of PER-1 and OXA-10 PCR products from
all positive isolates were determined following cycle sequen-
cing reactions (Big Dye Terminator Kit; Applied Biosystems,
Foster City, CA, USA) on an automated ABI PRISM 310 DNA
sequence analyser (Applied Biosystems).
RESULTS
Of the 287 clinical isolates of P. aeruginosa
obtained from patients hospitalised between
February 1999 and February 2000, 39% were
ceftazidime-resistant. When only the ICU isolates
were taken into account, the rate of ceftazidime
resistance was 62%. Of the 49 multiresistant ICU
isolates studied in detail (Table 1), 18 of the
tracheal isolates were considered to be colonising
bacteria, while the remaining isolates were con-
sidered to be causing infection. Among these 49
isolates, 98%, 92% and 96%, respectively, were
resistant to imipenem, aztreonam and cefepime,
and 41% and 37%, respectively, were resistant to
piperacillin and piperacillin–tazobactam. In addi-
tion to b-lactams, the 49 multiresistant isolates
were also resistant to aminoglycosides (gentami-
cin, tobramycin, netilmicin and amikacin) and to
ﬂuoroquinolones (ciproﬂoxacin and norﬂoxacin).
The double-disk synergy test indicated that only
18 (37%) of the 49 isolates were clavulanic acid-
inhibited ESBL producers (Table 1).
Forty-two (86%) of the 49 ceftazidime-resistant
isolates were positive by PCR for the blaPER-1
gene, 27 (55%) isolates were positive for a
blaOXA-10-like gene (OXA-10, -11, -14, -16 or -17),
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and 20 (41%) isolates were positive for both
b-lactamase genes. The disk diffusion results
indicated that all PER-1-positive isolates were
resistant to cefepime, imipenem and aztreonam;
three (7%) were susceptible and 21 (50%) were
moderately susceptible to piperacillin; and four
(10%) were susceptible and 20 (48%) were mod-
erately susceptible to piperacillin–tazobactam.
RAPD-PCR identiﬁed 16 different banding
patterns among the 42 PER-1-positive isolates,
but 25 (60%) of the 42 isolates belonged to two
distinct patterns (designated as patterns g and j;
Table 2), indicating the spread of clonally related
isolates among these patients.
When the blaPER-1 and blaOXA-10 genes from the
positive isolates were sequenced, all the PER-1
sequences and all the OXA-10 sequences were
identical and corresponded to the published
sequences for the PER-1 andOXA-10 genes [22,23].
DISCUSSION
P. aeruginosa is one of the most important path-
ogens among Gram-negative bacteria, causing
Table 1. Clinical features associated with ceftazidime-resistant Pseudomonas aeruginosa isolates and patients in the
intensive care unita
Isolate Hospitalisation Specimen
Infection /
colonisation
Patient’s underlying
disease or condition Treatment
Clinical
outcome DDST
PCR
RAPD
proﬁle
PER-1-type
enzyme
OXA-10-type
enzyme
1 10 ⁄ 2 ⁄ 99–14 ⁄ 12 ⁄ 99 TA Colonisation Pneumonia CIP, IP, CPZ Improved + + + j
2 25 ⁄ 3 ⁄ 99–20 ⁄ 10 ⁄ 99 TA Infection Pulmonary carcinoma CAZ Died + + – g
3 8 ⁄ 4 ⁄ 99–4 ⁄ 10 ⁄ 99 TA Infection Myelitis AK, CIP Improved – + + j
4 21 ⁄ 5 ⁄ 99–6 ⁄ 7 ⁄ 99 TA Colonisation Splenectomy AK, CAZ, CIP Improved – + + f
5 29 ⁄ 5 ⁄ 99–19 ⁄ 6 ⁄ 99 TA Infection Cerebral oedema PRL, CAZ, AK Died – + – g
6 11 ⁄ 6 ⁄ 99–17 ⁄ 6 ⁄ 99 TA Colonisation Hydatid cyst MEM Improved + + – g
7 10 ⁄ 6 ⁄ 99–28 ⁄ 6 ⁄ 99 TA Colonisation Bronchiolitis CAZ, GN Died + + – g
8 12 ⁄ 6 ⁄ 99–17 ⁄ 1 ⁄ 2000 TA Colonisation Myasthenia gravis AK, IP, CIP Improved – + + j
9 17 ⁄ 6 ⁄ 99–4 ⁄ 7 ⁄ 99 TA Colonisation Meningitis MEM, AK Died + + – g
10 22 ⁄ 6 ⁄ 99–30 ⁄ 8 ⁄ 99 TA Colonisation Pneumonia CAZ, GN Died – + + j
11 9 ⁄ 7 ⁄ 99–29 ⁄ 7 ⁄ 99 TA Colonisation DM, CRF CIP Died – + + f
12 9 ⁄ 7 ⁄ 99–29 ⁄ 7 ⁄ 99 TA Infection DM CIP Died – + + j
13 12 ⁄ 7 ⁄ 99–16 ⁄ 8 ⁄ 99 TA Infection Sepsis IP, NET Died – + – g
14 14 ⁄ 7 ⁄ 99–23 ⁄ 7 ⁄ 99 BAL Infection ARDS + sepsis NET, CIP Died + + – g
15 16 ⁄ 7 ⁄ 99–20 ⁄ 8 ⁄ 99 TA Colonisation Sepsis MEM, CAZ Improved – + + b
16 31 ⁄ 7 ⁄ 99–24 ⁄ 9 ⁄ 99 TA Infection ACA aneurysm MEM, CPZ Died – + + a
17 6 ⁄ 8 ⁄ 99–11 ⁄ 10 ⁄ 99 TA Infection Viral encephalitis CIP, NET Improved – + + h
18 12 ⁄ 8 ⁄ 99–10 ⁄ 9 ⁄ 99 TA Colonisation Aneurysm IP, AK Died – + – g
19 15 ⁄ 8 ⁄ 99–31 ⁄ 11 ⁄ 99 U Infection Amputation GN Improved + + – g
20 15 ⁄ 8 ⁄ 99–31 ⁄ 11 ⁄ 99 TA Colonisation Femur fracture GN Improved + + – o
21 19 ⁄ 8 ⁄ 99–18 ⁄ 11 ⁄ 99 TA Infection Acute renal failure MEM, AK Died – + + i
22 20 ⁄ 8 ⁄ 99–24 ⁄ 8 ⁄ 99 TA Infection Crush syndrome MEM, AK Died – – + –
23 20 ⁄ 8 ⁄ 99–24 ⁄ 9 ⁄ 99 U Infection Crush syndrome MEM, AK Died – – + –
24 20 ⁄ 8 ⁄ 99–24 ⁄ 9 ⁄ 99 TA Infection Crush syndrome MEM, AK Died – – + –
25 4 ⁄ 9 ⁄ 99–4 ⁄ 10 ⁄ 99 TA Colonisation Crush syndrome MEM, AK Improved – + + j
26 14 ⁄ 9 ⁄ 99–4 ⁄ 10 ⁄ 99 TA Infection Pneumonia CIP, CPZ Improved + + – l
27 24 ⁄ 9 ⁄ 99–25 ⁄ 9 ⁄ 99 TA Infection COPD SAM Died + + – g
28 26 ⁄ 9 ⁄ 99–16 ⁄ 11 ⁄ 99 TA Infection Skull fracture MEM, AK, CPZ Improved – + + j
29 26 ⁄ 9 ⁄ 99–16 ⁄ 11 ⁄ 99 TA Infection Skull fracture MEM, AK, CPZ Improved – + + j
30 3 ⁄ 10 ⁄ 99–14 ⁄ 11 ⁄ 99 TA Colonisation DM + ARDS MEM, NET Improved – + + j
31 12 ⁄ 10 ⁄ 99–7 ⁄ 12 ⁄ 99 TA Infection COPD CIP Improved – + – n
32 12 ⁄ 10 ⁄ 99–7 ⁄ 12 ⁄ 99 TA Infection COPD + CHF CIP Improved + + – k
33 15 ⁄ 10 ⁄ 99–31 ⁄ 11 ⁄ 99 TA Infection Intracerebral haematoma MEM, AK Improved + + + f
34 15 ⁄ 10 ⁄ 99–21 ⁄ 11 ⁄ 99 TA Infection AGN CIP Improved + + – e
35 17 ⁄ 10 ⁄ 99–7 ⁄ 12 ⁄ 99 TA Infection COPD + CHF CAZ, CIP Improved – + + g
36 23 ⁄ 10 ⁄ 99–12 ⁄ 11 ⁄ 99 TA Colonisation Multiple fractures MEM, AK Improved + + – c
37 23 ⁄ 10 ⁄ 99–12 ⁄ 11 ⁄ 99 TA Colonisation Head trauma CIP Improved + + – g
38 23 ⁄ 10 ⁄ 99–12 ⁄ 11 ⁄ 99 TA Colonisation ARDS MEM, AK Improved – + + g
39 25 ⁄ 10 ⁄ 99–5 ⁄ 12 ⁄ 99 TA Infection Carcinoma of the vesica IP, FEP Died – – + –
40 25 ⁄ 10 ⁄ 99–5 ⁄ 12 ⁄ 99 TA Infection Carcinoma of the vesica IP Died – – + –
41 26 ⁄ 10 ⁄ 99–7 ⁄ 2 ⁄ 2000 TA Colonisation Head trauma AK Died – + + m
42 7 ⁄ 11 ⁄ 99–28 ⁄ 1 ⁄ 2000 TA Infection COPD CAZ, CIP Unknown – + – d
43 17 ⁄ 11 ⁄ 99–20 ⁄ 11 ⁄ 99 TA Infection Multiple trauma NET Died + + – g
44 22 ⁄ 11 ⁄ 99–5 ⁄ 2 ⁄ 2000 TA Infection CO intoxication CIP, CPZ Improved + + – g
45 22 ⁄ 11 ⁄ 99–5 ⁄ 2 ⁄ 2000 TA Infection CO intoxication CIP, CPZ Improved – + – p
46 23 ⁄ 11 ⁄ 99–3 ⁄ 12 ⁄ 99 TA Colonisation Goodpasture syndrome MEM, AK Improved – + + j
47 25 ⁄ 11 ⁄ 99–28 ⁄ 12 ⁄ 99 U Infection Renal transplantation CIP Improved – – + –
48 6 ⁄ 12 ⁄ 99–9 ⁄ 12 ⁄ 99 TA Infection ALL IP Died – – + –
49 6 ⁄ 12 ⁄ 99–9 ⁄ 12 ⁄ 99 TA Infection ALL IP Died + + – c
Dates are presented as day ⁄month ⁄ year. TA, tracheal aspirate; U, urine; BAL, bronchoalveolar lavage ﬂuid; DDST, double-disk synergy test; AGN, acute glomerulonephritis;
DM, diabetes mellitus; CHF, congestive heart failure; ALL, acute lymphoblastic leukaemia; CRF, chronic renal failure; COPD, chronic obstructive pulmonary disease; ARDS,
acute respiratory distress syndrome; ACA, anterior communicating artery; FEP, cefepime; SAM, ampicillin–sulbactam; CPZ, cefoperazone; IP, imipenem; MEM, meropenem;
GN, gentamicin; NET, netilmicin; AK, amikacin; CIP, ciproﬂoxacin; CAZ, ceftazidime; PRL, piperacillin; TZP, piperacillin–tazobactam.
aSome patients (27, 43, 48 and 49) were transferred to the ICU from other units of the hospital.
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infections in up to 25% of ICU patients [24].
Ceftazidime resistance in P. aeruginosa is most
often caused by hyperproduction of the chromo-
somal AmpC b-lactamase or acquired ESBLs.
The PER-1 b-lactamase, a clavulanic acid-inhi-
bited ESBL that confers high-level ceftazidime
resistance, was found in 1997 to be distributed
widely among isolates of P. aeruginosa and Acine-
tobacter spp. in Turkey [9,10]. Detection of this
ESBL in P. aeruginosa and prevention of its spread
is important, as it confers resistance to widely
used b-lactams, including ceftazidime, aztreonam
and cefepime, and it appears to be transmissible
to other organisms such as Acinetobacter spp.
PER-1 has been identiﬁed previously in up to
38% of ceftazidime-resistant P. aeruginosa isolates,
with the results of ribotyping indicating the
spread of different clones [10,11,24]. PER-1 was
also identiﬁed in Salmonella typhimurium in 1995,
and in Providencia rettgeri and Klebsiella pneumoniae
in 2003 [25–28]. Studies conducted in Turkey in
1999 indicated that 46–62% of Acinetobacter spp.
and 11–23.7% of P. aeruginosa hospital isolates
produced PER-1, and that 5.3–17% of P. aerugi-
nosa isolates produced OXA-10-type b-lactamases
[9,10,29]. Oxacillin-hydrolysing enzymes are
found frequently in P. aeruginosa, and several
extended-spectrum OXA enzymes, which are
mostly OXA-10 derivatives, have been reported
in P. aeruginosa isolates from Turkey [13–15,29]. In
contrast to previous reports, the present study did
not identify any mutants or derivatives of OXA-10
b-lactamases in the P. aeruginosa isolates exam-
ined. The extent of the distribution of PER-1
outside Turkey remains unknown, but multiple
reports have emerged from France, Italy, Belgium
and Korea of PER-1-positive P. aeruginosa, Acine-
tobacter spp. [23,30–33], Proteus mirabilis and
Alcaligenes faecalis isolates [34,35].
The results of the present study indicated that
PER-1 was present in 86%, and OXA-10 in 55%,
of the ceftazidime-resistant P. aeruginosa isolates,
with 41% producing both PER-1 and OXA-10.
According to previous studies, P. aeruginosa iso-
lates with a ceftazidime-resistant and piperacillin-
susceptible phenotype may be suspected of
carrying the PER-1 gene, since PER-1 shows poor
activity against piperacillin [8,31,36]. However, in
the present study, the piperacillin susceptibility
was also low, suggesting that other resistance
mechanisms, such as overexpression of chromo-
somal AmpC, might also be present. The double-
disk synergy test may fail to detect strains that
produce PER-1- and OXA-derived enzymes, and
only 37% (18 ⁄ 49) of the PER-1-positive isolates
were positive with a disk distance of 25–30 mm in
this study. Similarly, Yong et al. [32] reported that
53 (52%) of 102 Acinetobacter baumannii isolates
were PER-1-positive, although only 17 were pos-
itive in the double-disk synergy test, even with an
edge-to-edge disk distance of 10 mm.
Ceftazidime resistance rates of 18–86% have
been reported previously in P. aeruginosa isolates
from hospitalised patients in Turkey [37–39].
Rates of b-lactam resistance in the present study
during 1999–2000 were higher than those in
previous reports. A multicentre study reported
ceftazidime resistance in 28% of P. aeruginosa
isolates, with PER-1-type b-lactamases being
found in 38% of the ceftazidime-resistant isolates
[9]. The discrepancy may be caused by the fact
that the present isolates were all from ICU
patients, whereas previous studies examined
isolates from both ICU and non-ICU patients
hospitalised in different university hospitals in
different regions of Turkey [9]. As shown in
Table 1, 37% of the patients in the present study
were considered to be colonised with P. aerugi-
nosa. Colonised patients represent a potential
reservoir of (epidemic) strains from which other
patients can be colonised via cross-acquisition.
Several studies have demonstrated that cross-
acquisition may play a signiﬁcant role in nosoco-
mial outbreaks involving P. aeruginosa [40,41]. The
results of the present study show that isolates
of P. aeruginosa producing PER-1 and OXA-10
b-lactamases are encountered frequently in this
Turkish hospital, and that their clonal diversity
Table 2. RAPD proﬁles of PER-1-positive Pseudomonas
aeruginosa isolates (n = 42)
RAPD proﬁle PER-1 (n) PER and OXA-10 (n)
a 1
b 1
c 2
d 1
e 1
f 3
g 13 2
h 1
i 1
j 10
k 1
l 1
m 1
n 1
o 1
p 1
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and high prevalence indicate a considerable
potential for spread among patients.
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